3-(4-吗啉基)苯酚 | 27292-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 3-(4-吗啉基)苯酚
• 中文别名: 3-吗啉苯酚
• 英文名称: 3-(4-morpholino)phenol
• 英文别名: 3-morpholinophenol；N-m-hydroxyphenylmorpholine；m-Morpholino-phenol；3-(4-morpholinyl)-phenol；AMA58；3-morpholin-4-ylphenol
• CAS: 27292-49-5
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD00051675
• 分子量: 179.219
• InChiKey: BMGSGGYIUOQZBZ-UHFFFAOYSA-N

物化性质

• 熔点：
  136 °C
• 沸点：
  362.6±37.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会发生分解。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密的容器中。存放在阴凉、干燥的地方。

SDS

Name:	3-Morpholinophenol 97% Material Safety Data Sheet
Synonym:	N-(3-Hydroxyphenyl)morpholin
CAS:	27292-49-5

Section 1 - Chemical Product MSDS Name:3-Morpholinophenol 97% Material Safety Data Sheet
Synonym:N-(3-Hydroxyphenyl)morpholin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
27292-49-5	3-Morpholinophenol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 27292-49-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pink
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 132 - 134 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H13NO2
Molecular Weight: 179.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, bases, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 27292-49-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Morpholinophenol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 27292-49-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 27292-49-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 27292-49-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4-吗啉基)苯酚 在 三氯氧磷 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 81.0h， 生成 1-(2-羟基-4-N-吗啉基苯基)乙酮
  参考文献：
  名称：

  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold

  摘要：

  Phosphoinositide 3-kinases (PI3-Ks) are an ubiquitous class of signaling enzymes that regulate diverse cellular processes including growth, differentiation, and motility. Physiological roles of PI3-Ks have traditionally been assigned using two pharmacological inhibitors, LY294002 and wortmannin. Although these compounds are broadly specific for the PI3-K family, they show little selectivity among family members, and the development of isoform-specific inhibitors of these enzymes has been long anticipated. Herein, we prepare compounds from two classes of arylmorpholine PI3-K inhibitors and characterize their specificity against a comprehensive panel of targets within the PI3-K family. We identify multiplex inhibitors that potently inhibit distinct subsets of PI3-K isoforms, including the first selective inhibitor of p110beta/p110delta (IC50 p110beta = 0.13 muM, p110delta = 0.63 muM). We also identify trends that suggest certain PI3-K isoforms may be more sensitive to potent inhibition by arylmorpholines, thereby guiding future drug design based on this pharmacophore. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.06.022
• 作为产物：
  描述：

  3-苄氧基溴苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 氢气 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲醇 、 乙酸乙酯 、 甲苯 为溶剂， 80.0 ℃ 、275.8 kPa 条件下， 反应 56.0h， 生成 3-(4-吗啉基)苯酚
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
  [FR] COMPOSITION PHARMACEUTIQUE DESTINEE A PREVENIR ET A TRAITER DES MALADIES OSSEUSES METABOLIQUES, CONTENANT DES DERIVES D'ALPHA-ARYLMETHOXYACRYLATE

  摘要：

  本发明涉及使用特定的α-芳基甲氧基丙烯酸酯衍生物，或其药理学上可接受的盐或溶剂，用于预防和治疗代谢性骨疾病。

  公开号：

  WO2005123054A1

文献信息

• [DE] 2-HETEROARYLCARBONSÄUREAMIDE<br/>[EN] 2-HETEROARYL CARBOXAMIDES<br/>[FR] 2-HETEROARYLCARBOXAMIDES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2003104227A1

  公开（公告）日：2003-12-18

  Die Erfindung betrifft neue 2-Heteroarylcarbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten und zur Verbesserung der Wahrnehmung, Konzentrationsleistung, Lernleistung und/oder Gedächtnisleistung. (I): in welcher R1 1-Aza-bicyclo [2.2.2]oct-3-yl, welches gegebenenfalls über das Sticktoffätom mit einem Rest ausgewählt aus der Gruppe C1-C4-Alkyl, Benzyl und Oxy substituiert ist, A Sauerstoff oder Schwefel, der Ring B Benzo oder Pyrido, die jeweils gegebenenfalls durch Reste aus der Reihe Halogen, Cyano, Formyl, Trifluormethyl, Trifluormethoxy, Nitro, Amino, C1-C6-Alkyl und C1-C6-Alkoxy substituiert sind, E C≡C, Aryl und Heteroaryl, wobei Aryl und Heteroaryl durch Reste aus der Reihe Halogen, Cyano, Trifluormethyl, Trifluormethyl, Trifluormethoxy, Nitro, Amino, C1-C6-Alkoxy und C1-C6-Alkyl substituiert sein Können, bedeuten, sowie die Solvate, Salze oder Solvate der Salze dieser Verbindungen.

  这项发明涉及新的2-杂环芳基羧酰胺及其用于制备用于治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆能力的药物的用途。其中，R1为1-Aza-bicyclo[2.2.2]oct-3-yl，可能通过氮原子与来自C1-C4-烷基、苄基和氧的基团中的一种取代，A为氧或硫，环B为苯并或吡啶，并且可以通过来自卤素、氰基、甲酰基、三氟甲基、三氟甲氧基、硝基、氨基、C1-C6-烷基和C1-C6-烷氧基的基团取代，E为C≡C、芳基和杂环芳基，其中芳基和杂环芳基可以通过来自卤素、氰基、三氟甲基、三氟甲基、三氟甲氧基、硝基、氨基、C1-C6-烷氧基和C1-C6-烷基的基团取代，以及这些化合物的溶剂化合物、盐或盐的溶剂化合物。
• A Novel Morpholine-Based Rhodamine Fluorescent Chemosensor for the Rapid Detection of Hg²⁺ Ions
  作者：Hwalkee Park、Mergu Naveen、Kyoung-Lyong An、Kun Jun、Young-A Son

  DOI：10.1166/jnn.2019.16709

  日期：2019.11.1

  A novel rhodamine-based receptor bearing a morpholine (RDM) was developed as a fluorescent chemosensor with high selectivity toward Hg²⁺. After the addition of Hg²⁺ to RDM, the color of the solution changed from colorless to pink, and the new absorption band appears at 580 nm. The fluorescent of RDM appears to orange color in the presence of Hg²⁺. Upon the addition of Hg²⁺, ring-opening of the corresponding spirolactam gives rise to fluorescence, and a 1:1 metal-ligand complex formed.

  一种基于罗丹明的含吗啡基团的受体（RDM）被开发为一种具有高选择性对Hg²⁺的荧光化学传感器。在向RDM中加入Hg²⁺后，溶液的颜色从无色变为粉红色，并出现了新的吸收带，波长为580纳米。在Hg²⁺存在时，RDM的荧光呈橙色。加入Hg²⁺后，相应的螺内酰胺环开启导致荧光产生，并形成1:1的金属配体络合物。
• [EN] 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY<br/>[FR] BENZO[B]THIOPHENES A SUBSTITUTION 3-ARYLOXY ET 3-HETEROARYLOXY EN TANT QU'AGENTS THERAPEUTIQUES A ACTIVITE PI3K
  申请人：WARNER LAMBERT CO

  公开号：WO2004108715A1

  公开（公告）日：2004-12-16

  The present invention provides benzo[b]thiophenes of Formula (I), wherein R1, R2, R3, R4, R5, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I).

  本发明提供了式(I)的苯并[b]噻吩，其中R1、R2、R3、R4、R5和L具有规范中为其定义的任何值，以及药用可接受的盐，这些盐作为治疗疾病和状况的药剂是有用的，包括炎性疾病、心血管疾病和癌症。另外还提供了包含一个或多个式(I)化合物的药物组合物。
• [EN] PROCESS FOR DEOXYFLUORINATION OF PHENOLS<br/>[FR] PROCÉDÉ DE DÉSOXYFLUORATION DE PHÉNOLS
  申请人：STUDIENGESELLSCHAFT KOHLE MBH

  公开号：WO2019025137A1

  公开（公告）日：2019-02-07

  The present invention refers to a process for transition-meta!-assisted 18F- deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials; tolerance of moisture and ambient atmosphere, large substrate scope, and translatability to generate doses appropriate for positron emission tomography (PET) imaging.

  本发明涉及一种过渡金属催化的18F-脱氧氟化酚的过程。这种转化得益于容易获得的酚作为起始材料；能够容忍水分和大气环境，具有广泛的底物范围，并且可以转化为适合正电子发射断层扫描（PET）成像的剂量。
• Novel amino acid ester and reagent composition for detecting leucocytes or elastase in body liquid
  申请人：KYOTO DAIICHI KAGAKU CO., LTD.

  公开号：EP0661280A1

  公开（公告）日：1995-07-05

  An amino acid ester of the formula: (X-O-A-)n-Y in which X is derived from an aromatic or heterocyclic compound: X-OH or its derivative; A is a residue of a L-amino acid, n is an integer of at least 2, and Y is a N-substituent of an amino acid derived from a compound having the same or different two or more carbonyl or sulfonyl groups which is formed from a single or complex compound selected from the group consisting of noncyclic or cyclic hydrocarbons having 1 to 10 carbon atoms, saturated or unsaturated heterocyclic compounds, aromatic compounds, organosilicon compounds having 1 to 10 silicon atoms, monosaccharides and oligosaccharide comprising 2 to 10 monosaccharides, all of which may have a substituent and/or a hetero atom to form the complex, which ester is specifically hydrolyzed by leucocytes or elastase.

  公式为(X-O-A-)n-Y的氨基酸酯，其中X源自芳香族或杂环化合物：X-OH或其衍生物；A是L-氨基酸的残基，n是至少为2的整数，Y是源自具有相同或不同的两个或更多个羰基或磺酰基的化合物的氨基酸的N-取代基，该化合物由选择自非环烃或环烃的群组成的单一或复杂化合物形成，该群包括具有1至10个碳原子的饱和或不饱和杂环化合物、芳香族化合物、具有1至10个硅原子的有机硅化合物、由2至10个单糖组成的单糖和寡糖，所有这些化合物均可具有取代基和/或杂原子以形成复合物，该酯特异地被白细胞或弹性蛋白酶水解。

表征谱图